Venture Capital Investors

MPM Capital

MPM Capital is a VC investing group that assists tech companies seeking to achieve their full potential.

Venture Investor Overview

Venture Investor
MPM Capital
Status
Active
Investor Type
Venture Capital
Activity Level
263 transactions
Funds Raised
At least $2.7 billion
Industry Focus
Biopharmaceutical
Medical Devices & Instruments

Contact Information

Contact
Luke Evnin
Title
Managing Director
Mailing Address
601 Gateway Boulevard 350
South San Francisco, CA 94080
USA
Phone
(650) 553-3300
Website
www.mpmcapital.com
Email Address
Not Recorded

Background Information

Overview
MPM invests in biotechnology, specialty pharma, medical technology, and related companies that provide innovative medical products and requisite services to the healthcare industry, irrespective of geography, stage of development and therapeutic area. We seek to maximize value creation by focusing on inflection points in the development of companies, such as the achievement of clinical proof-of-concept data, the achievement of early commercial success, and by reinvigorating commercial platforms with potentially high growth assets.
Profile
MPM Capital LinkedIn Company Profile
Social Media
MPM Capital Company Twitter Account
Company News
MPM Capital News
Facebook
MPM Capital on Facebook
YouTube
MPM Capital on YouTube
Last Transaction
2/15/2024

Transaction History

Our records indicate that MPM Capital invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
NextPoint Therapeutics
2/15/2024
$42,500,000
Firefly Bio
2/15/2024
$94,000,000
AstronauTx
10/9/2023
$59,008,000
Deka Biosciences
9/28/2023
$20,000,000
ReCode Therapeutics
9/19/2023
$50,000,000
Arialys Therapeutics
9/13/2023
$58,000,000
Crossbow Therapeutics
7/11/2023
$80,000,000
ReNAgade Therapeutics
5/24/2023
$300,000,000
ElevateBio
5/24/2023
$401,000,000
NextPoint Therapeutics
1/10/2023
$80,000,000
Photys Therapeutics
9/8/2022
$75,000,000
Aktis Oncology
8/26/2022
$84,000,000
Orna Therapeutics
8/17/2022
$221,000,000
CODA Biotherapeutics
12/6/2021
$28,000,000
ReCode Therapeutics
10/23/2021
$80,000,000
Frontier Medicines
7/20/2021
$88,500,000
Umoja Biopharma
6/16/2021
$210,000,000
Entrada Therapeutics
4/1/2021
$116,000,000
Aktis Oncology
3/19/2021
$72,000,000
Orna Therapeutics
2/25/2021
$80,000,000
Umoja Biopharma
11/20/2020
$53,000,000
Dyne Therapeutics
8/11/2020
$115,000,000
Cullinan Oncology
6/5/2020
$98,500,000
iTeos Therapeutics
4/2/2020
$125,000,000
ElevateBio
3/31/2020
$170,000,000
ReCode Therapeutics
3/27/2020
$80,000,000
Triplet Therapeutics
12/18/2019
$59,000,000
Werewolf Therapeutics
11/21/2019
$56,000,000
CODA Biotherapeutics
11/7/2019
$15,000,000
Amphivena Therapeutics
9/25/2019
$62,000,000
Repare Therapeutics
9/5/2019
$82,500,000
Oncorus
8/22/2019
$79,500,000
Frontier Medicines
6/27/2019
$67,000,000
Dyne Therapeutics
4/4/2019
$50,000,000
TriNetX
3/14/2019
$40,000,000
Entrada Therapeutics
12/19/2018
$59,000,000
Harpoon Therapeutics
11/13/2018
$70,000,000
CoDa Therapeutics
9/14/2018
$19,000,000
Twentyeight-Seven Therapeutics
9/7/2018
$65,000,000
TCR2 Therapeutics
3/22/2018
$125,000,000
Semma Therapeutics
12/1/2017
$114,000,000
Cullinan Oncology
10/4/2017
$150,000,000
Repare Therapeutics
6/23/2017
$68,000,000
Harpoon Therapeutics
5/26/2017
$45,000,000
RHYTHM Health
2/18/2017
$41,000,000
Iconic Therapeutics
8/10/2016
$10,000,000
Oncorus
7/20/2016
$57,000,000
Blade Therapeutics
6/20/2016
$45,000,000
Potenza Therapeutics
3/31/2016
$15,000,000
Harpoon Therapeutics
3/31/2016
$15,000,000
Tizona Therapeutics
3/8/2016
$43,000,000
Iconic Therapeutics
1/11/2016
$40,000,000
TCR2 Therapeutics
12/31/2015
$5,800,000
RHYTHM Health
12/31/2015
$15,000,000
OSS Healthcare
12/31/2015
$200,000
True North Therapeutics
12/3/2015
$40,000,000
23andMe
10/14/2015
$115,000,000
Tizona Therapeutics
9/30/2015
$13,500,000
Syndax Pharmaceuticals
8/24/2015
$80,000,000
Valeritas Holdings
6/30/2015
$15,600,000
Sideris Pharmaceuticals
6/30/2015
$4,500,000
Amphivena Therapeutics
5/4/2015
$14,000,000
True North Therapeutics
4/7/2015
Unknown
Tetherex Pharmaceuticals
3/31/2015
$1,263,000
Florida Healthcare Analytics
3/31/2015
$1,300,000
Iconic Therapeutics
3/31/2015
$11,258,000
Selexys Pharmaceuticals
3/31/2015
$3,873,000
Semma Therapeutics
3/25/2015
$44,000,000
Clinical Ink
3/19/2015
$9,860,223
Chiasma
2/27/2015
$70,000,000
Valeritas Holdings
12/31/2014
$17,561,000
Potenza Therapeutics
12/31/2014
$15,000,000
Vascular Pharmaceuticals
12/31/2014
$1,000,000
Mitokyne
12/31/2014
$15,000,000
Raze Therapeutics
10/14/2014
$24,000,000
Cerecor
7/21/2014
$16,259,016
TriNetX
6/30/2014
$13,015,000
True North Therapeutics
6/17/2014
$22,000,000
Proteon Therapeutics
5/16/2014
$45,000,000
Iconic Therapeutics
4/16/2014
$20,000,000
Florida Healthcare Analytics
3/31/2014
$2,000,000
Trivascular Technologies
11/18/2013
$40,000,000
Sideris Pharmaceuticals
10/23/2013
$32,000,000
Mitokyne
10/21/2013
$45,000,000
Rhythm Pharmaceuticals
9/30/2013
$11,000,000
RWHD
9/30/2013
$1,600,000
Theraclone Sciences
9/30/2013
$4,000,000
Amphivena Therapeutics
9/30/2013
$14,000,000
True North Therapeutics
9/4/2013
Unknown
iPierian
9/4/2013
$30,000,000
Syndax Pharmaceuticals
8/27/2013
$26,600,000
InformedDNA
7/9/2013
$3,000,000
Aires Pharmaceuticals
6/30/2013
$8,000,000
Radius Health
4/26/2013
$43,000,000
Costim Pharmaceuticals
3/31/2013
$10,005,000
Theraclone Sciences
3/25/2013
$14,000,000
Nevro
3/7/2013
$48,000,000
Florida Healthcare Analytics
12/31/2012
$200,000
Trivascular Technologies
12/31/2012
$24,600,000
23andMe
12/11/2012
$50,000,000
Rhythm Pharmaceuticals
9/30/2012
$11,000,000
Selexys Pharmaceuticals
9/19/2012
$23,000,000
Vascular Pharmaceuticals
9/13/2012
$16,000,000
Chiasma
7/24/2012
$38,500,000
Ceregene
6/30/2012
$7,655,000
Astute Medical
6/7/2012
$40,400,000
Trivascular Technologies
6/5/2012
$60,000,000
Rhythm Pharmaceuticals
6/4/2012
$25,000,000
Celladon
5/7/2012
$10,000,000
Kalidex Pharmaceuticals
3/31/2012
$6,499,900
Aires Pharmaceuticals
3/31/2012
$6,000,000
Aratana Therapeutics
3/31/2012
$7,500,000
Rhythm Pharmaceuticals
12/31/2011
$12,500,000
Theraclone Sciences
12/31/2011
$985,200
NeuroTherapeutics Pharma
12/31/2011
$12,000,200
Acceleron Pharma
12/23/2011
$30,000,000
Allozyne
12/23/2011
Unknown
Aratana Therapeutics
12/7/2011
$15,000,000
Epizyme
9/30/2011
$19,000,000
Cardiac Dimensions
9/30/2011
$6,447,000
Valeritas Holdings
9/12/2011
$150,000,000
Theraclone Sciences
9/8/2011
$10,600,000
Nevro
7/20/2011
$58,000,000
Verastem
7/14/2011
$32,000,000
Radius Health
5/24/2011
$91,000,000
Conatus Pharmaceuticals
4/13/2011
$7,500,000
Cerimon Pharmaceuticals
3/31/2011
$130,000
Kalidex Pharmaceuticals
3/31/2011
$8,500,000
23andMe
1/7/2011
$9,000,000
Aratana Therapeutics
1/7/2011
$20,000,000
Allozyne
12/31/2010
$1,500,200
Cardiac Dimensions
12/31/2010
$6,446,900
Verastem
11/16/2010
$16,000,000
Aires Pharmaceuticals
11/12/2010
$20,000,000
Ceregene
11/11/2010
$11,500,000
Rhythm Pharmaceuticals
9/8/2010
$19,000,000
EndoGastric Solutions
8/30/2010
$30,000,000
Trivascular Technologies
7/13/2010
$60,000,000
iPierian
7/8/2010
$22,000,000
NeuroTherapeutics Pharma
5/20/2010
$43,000,000
Rhythm Pharmaceuticals
3/15/2010
$21,000,000
Syndax Pharmaceuticals
2/3/2010
$9,000,000
Alnara Pharmaceuticals
1/28/2010
$35,000,000
Trivascular Technologies
11/16/2009
$30,000,000
Epizyme
10/7/2009
$32,000,000
PrimeraDx
9/21/2009
$20,000,000
Surface Logix
6/30/2009
$5,400,000
Xanodyne Pharmaceuticals
6/4/2009
$38,000,000
Elixir Pharmaceuticals
5/19/2009
$12,000,000
Peptimmune
3/31/2009
$6,349,800
Pacira Pharmaceuticals
3/31/2009
$2,433,000
Surface Logix
3/9/2009
$20,000,000
Proteon Therapeutics
3/5/2009
$38,000,000
Chiasma
1/13/2009
$11,000,000
Pacira Pharmaceuticals
12/31/2008
$55,000,000
Valeritas Holdings
12/31/2008
$9,999,800
KaloBios Pharmaceuticals
12/22/2008
$12,000,000
Radius Health
11/20/2008
$15,000,000
Seredigm
9/30/2008
$700,000
Valeritas Holdings
9/30/2008
$39,999,700
ForteBio
9/24/2008
$25,000,000
Peplin
8/29/2008
$24,000,000
Xoft
8/4/2008
$25,000,000
Peptimmune
7/16/2008
$8,900,000
Chiasma
6/30/2008
$2,896,800
Alinea Pharmaceuticals
3/31/2008
$2,000,000
Pacira Pharmaceuticals
3/31/2008
$14,999,900
Trivascular Technologies
3/31/2008
$65,000,000
EKR Therapeutics
3/10/2008
$145,000,000
Arriva Pharmaceuticals
2/29/2008
$6,000,000
Peptimmune
1/17/2008
$8,200,000
PrimeraDx
1/8/2008
$21,000,000
AVEO Oncology
12/31/2007
$5,499,600
Cardiac Dimensions
12/18/2007
$35,500,000
Acceleron Pharma
10/30/2007
$31,000,000
Allozyne
10/26/2007
$30,000,000
Elixir Pharmaceuticals
9/30/2007
$28,030,100
Neuromed Pharmaceuticals
8/21/2007
$53,300,000
Xanodyne Pharmaceuticals
7/27/2007
$25,000,000
KaloBios Pharmaceuticals
7/23/2007
$20,000,000
Cardiac Dimensions
6/30/2007
$4,004,000
CoLucid Pharmaceuticals
6/30/2007
$8,250,000
Athersys
6/12/2007
$65,000,000
QuatRx Pharmaceuticals
5/22/2007
$44,000,000
Portola Pharmaceuticals
5/7/2007
$70,000,000
AVEO Oncology
5/3/2007
$53,000,000
Cellerant Therapeutics
4/26/2007
$4,400,000
Metabolex
4/19/2007
$32,000,000
Xoft
4/5/2007
$33,200,000
Radius Health
4/3/2007
$57,500,000
Syndax Pharmaceuticals
4/3/2007
$40,000,000
Innovative Spinal Technologies
3/31/2007
$18,999,800
Seredigm
3/31/2007
$2,499,900
ARYx Therapeutics
3/22/2007
$30,399,700
Theraclone Sciences
3/19/2007
$29,000,000
LifeSync
1/9/2007
$17,000,000
Radius Health
12/31/2006
$17,860,000
Verus Pharmaceuticals
12/31/2006
$40,000,000
NeoVista
12/8/2006
$41,000,000
NBI Development
12/4/2006
$5,500,000
Elixir Pharmaceuticals
11/29/2006
$46,000,000
Orexigen Therapeutics
11/22/2006
$30,000,000
Chiasma
11/15/2006
$44,000,000
EnteroMedics
7/19/2006
$45,200,000
Elixir Pharmaceuticals
6/30/2006
$18,400,000
Verus Pharmaceuticals
6/30/2006
$28,000,000
VLST
6/16/2006
$55,000,000
MacroGenics
5/17/2006
$45,000,000
NeoRx
4/27/2006
$65,000,000
Helicos BioSciences
3/15/2006
$40,000,000
Neuromed Pharmaceuticals
3/8/2006
$25,000,000
Archus Orthopedics
1/18/2006
$35,000,000
Hypnion
12/19/2005
$20,100,000
Portola Pharmaceuticals
11/8/2005
$46,000,000
Cerimon Pharmaceuticals
10/26/2005
$70,000,000
Alinea Pharmaceuticals
10/20/2005
$45,000,000
Innovative Spinal Technologies
8/2/2005
$39,000,000
Affymax
7/18/2005
$60,000,000
Peptimmune
7/15/2005
$20,400,000
PrimeraDx
7/11/2005
$11,000,000
Idun Pharmaceuticals
6/30/2005
$38,610,000
Amphora Discovery
6/30/2005
$9,549,800
AVEO Oncology
6/30/2005
$5,000,100
Verus Pharmaceuticals
6/9/2005
$98,000,000
Somaxon Pharmaceuticals
6/6/2005
$65,000,000
Oxagen Limited
5/23/2005
$59,800,000
Cellerant Therapeutics
5/11/2005
$16,000,000
Theraclone Sciences
3/31/2005
$800,000
Hemosense
3/31/2005
$3,355,100
KaloBios Pharmaceuticals
3/16/2005
$20,000,000
Perlegen Sciences
2/28/2005
$74,000,000
CHF Solutions
1/19/2005
$22,900,000
QuatRx Pharmaceuticals
12/13/2004
$31,000,000
Amphora Discovery
12/8/2004
$20,000,000
EnteroMedics
11/30/2004
$16,900,000
Accelerator Alumni
11/18/2004
$11,800,000
Neosil
11/8/2004
$32,000,000
PharmAthene
10/12/2004
$50,000,000
Pharmasset
8/10/2004
$40,000,000
Ceregene
8/4/2004
$32,000,000
Idun Pharmaceuticals
6/14/2004
$27,000,000
Cellular Genomics
6/14/2004
$34,900,000
Affymax
4/13/2004
$20,000,000
Restore Medical
3/18/2004
$26,500,000
Cardiac Dimensions
3/17/2004
$15,000,000
TaiGen Biotechnology
3/16/2004
$38,000,000
Helicos BioSciences
2/2/2004
$27,000,000
Cellular Genomics
1/21/2004
$22,300,000
Portola Pharmaceuticals
12/8/2003
$21,000,000
Intercell AG
11/20/2003
$50,000,000
Neuromed Pharmaceuticals
11/4/2003
$32,000,000
CoTherix
10/14/2003
$55,000,000
Elixir Pharmaceuticals
10/13/2003
$40,500,000
Critical Technologies
10/8/2003
$56,000,000
Hemosense
8/7/2003
Unknown
Tercica
7/17/2003
$44,000,000
Rigel Pharmaceuticals
6/27/2003
$46,000,000
QuatRx Pharmaceuticals
6/10/2003
$28,000,000
Cellerant Therapeutics
5/29/2003
$10,000,000
Epigenomics AG
4/3/2003
$22,500,000
Hypnion
3/17/2003
$47,500,000
Peptimmune
3/12/2003
$41,200,000
Synergia Pharma
3/11/2003
$2,000,000

 

Investor Contacts

Title
Name
Email & Social
Managing Director
Luke Evnin
  Luke Evnin LinkedIn Profile  Luke Evnin Twitter Account  Luke Evnin News  Luke Evnin on Facebook
Managing Director
Todd Foley
  Todd Foley LinkedIn Profile  Todd Foley Twitter Account  Todd Foley News  Todd Foley on Facebook
Managing Director
Ansbert Gadicke
  Ansbert Gadicke LinkedIn Profile  Ansbert Gadicke Twitter Account  Ansbert Gadicke News  Ansbert Gadicke on Facebook
Managing Director
Bard Geesaman
  Bard Geesaman LinkedIn Profile  Bard Geesaman Twitter Account  Bard Geesaman News  Bard Geesaman on Facebook
Principal
Phil Gutry
  Phil Gutry LinkedIn Profile  Phil Gutry Twitter Account  Phil Gutry News  Phil Gutry on Facebook
Managing Director
Vaughn Kailan
  Vaughn Kailan LinkedIn Profile  Vaughn Kailan Twitter Account  Vaughn Kailan News  Vaughn Kailan on Facebook
Principal
Corey McCann
  Corey McCann LinkedIn Profile  Corey McCann Twitter Account  Corey McCann News  Corey McCann on Facebook
Managing Director
Gary Patou
  Gary Patou LinkedIn Profile  Gary Patou Twitter Account  Gary Patou News  Gary Patou on Facebook
Managing Director
James Scopa
  James Scopa LinkedIn Profile  James Scopa Twitter Account  James Scopa News  James Scopa on Facebook
Managing Director
Kazumi Shiosaki
  Kazumi Shiosaki LinkedIn Profile  Kazumi Shiosaki Twitter Account  Kazumi Shiosaki News  Kazumi Shiosaki on Facebook
Managing Director
Gregory Sieczkiewicz
  Gregory Sieczkiewicz LinkedIn Profile  Gregory Sieczkiewicz Twitter Account  Gregory Sieczkiewicz News  Gregory Sieczkiewicz on Facebook
Managing Director
Elizabeth Stoner
  Elizabeth Stoner LinkedIn Profile  Elizabeth Stoner Twitter Account  Elizabeth Stoner News  Elizabeth Stoner on Facebook

 

Funds

Our database includes the following fund closing(s) for MPM Capital. If we are missing funds, please contact us.

Fund Description
Vintage Date
Fund Amount
Oncology Fund
2/26/2020
$100,000,000
BioVentures 2018
2/21/2019
$400,000,000
MPM BioVentures VI
5/12/2015
$400,000,000
MPM BioVentures V
2/12/2010
$300,000,000
MPM BioVentures IV
3/31/2006
$552,000,000
MPM BioVentures III
12/15/2002
$949,000,000

 

Portfolio Companies

MPM Capital has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company
23andMe
Accelerator Alumni
Acceleron Pharma
Affymax
Aires Pharmaceuticals
Aktis Oncology
Alinea Pharmaceuticals
Allozyne
Alnara Pharmaceuticals
Amphivena Therapeutics
Amphora Discovery
Aratana Therapeutics
Archus Orthopedics
Arialys Therapeutics
Arriva Pharmaceuticals
ARYx Therapeutics
AstronauTx
Astute Medical
Athersys
AVEO Oncology
Blade Therapeutics
Cardiac Dimensions
Celladon
Cellerant Therapeutics
Cellular Genomics
Cerecor
Ceregene
Cerimon Pharmaceuticals
CHF Solutions
Chiasma
Clinical Ink
CODA Biotherapeutics
CoDa Therapeutics
CoLucid Pharmaceuticals
Conatus Pharmaceuticals
Costim Pharmaceuticals
CoTherix
Critical Technologies
Crossbow Therapeutics
Cullinan Oncology
Deka Biosciences
Dyne Therapeutics
EKR Therapeutics
ElevateBio
Elixir Pharmaceuticals
EndoGastric Solutions
EnteroMedics
Entrada Therapeutics
Epigenomics AG
Epizyme
Firefly Bio
Florida Healthcare Analytics
ForteBio
Frontier Medicines
Harpoon Therapeutics
Helicos BioSciences
Hemosense
Hypnion
Iconic Therapeutics
Idun Pharmaceuticals
InformedDNA
Innovative Spinal Technologies
Intercell AG
iPierian
iTeos Therapeutics
Kalidex Pharmaceuticals
KaloBios Pharmaceuticals
LifeSync
MacroGenics
Metabolex
Mitokyne
NBI Development
NeoRx
Neosil
NeoVista
Neuromed Pharmaceuticals
NeuroTherapeutics Pharma
Nevro
NextPoint Therapeutics
Oncorus
Orexigen Therapeutics
Orna Therapeutics
OSS Healthcare
Oxagen Limited
Pacira Pharmaceuticals
Peplin
Peptimmune
Perlegen Sciences
Pharmasset
PharmAthene
Photys Therapeutics
Portola Pharmaceuticals
Potenza Therapeutics
PrimeraDx
Proteon Therapeutics
QuatRx Pharmaceuticals
Radius Health
Raze Therapeutics
ReCode Therapeutics
ReNAgade Therapeutics
Repare Therapeutics
Restore Medical
RHYTHM Health
Rhythm Pharmaceuticals
Rigel Pharmaceuticals
RWHD
Selexys Pharmaceuticals
Semma Therapeutics
Seredigm
Sideris Pharmaceuticals
Somaxon Pharmaceuticals
Surface Logix
Syndax Pharmaceuticals
Synergia Pharma
TaiGen Biotechnology
TCR2 Therapeutics
Tercica
Tetherex Pharmaceuticals
Theraclone Sciences
Tizona Therapeutics
TriNetX
Triplet Therapeutics
Trivascular Technologies
True North Therapeutics
Twentyeight-Seven Therapeutics
Umoja Biopharma
Valeritas Holdings
Vascular Pharmaceuticals
Verastem
Verus Pharmaceuticals
VLST
Werewolf Therapeutics
Xanodyne Pharmaceuticals
Xoft

 

 

 

 

Browse more venture capital investors:

MPL Ventures | MPower Partners

 

Share this article

 

About Our Venture Capital Investor Database

This VC firm profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.